# Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Study · id `cardio:ct-nct06291376` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06291376](<https://clinicaltrials.gov/study/NCT06291376>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06291376

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 584 participants.

## Technical summary

Registry record NCT06291376. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-29 (actual); primary completion 2026-01-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 584 participants (enrolled count; ClinicalTrials.gov record NCT06291376, source copy `cardio:ctgov-nct06291376-2026-10-02`, retrieved 2026-11-18)
- Started: 2024-03-29 (actual) (ClinicalTrials.gov record NCT06291376, source copy `cardio:ctgov-nct06291376-2026-10-02`, retrieved 2026-11-18)
- Primary completion: 2026-01-05 (actual) (ClinicalTrials.gov record NCT06291376, source copy `cardio:ctgov-nct06291376-2026-10-02`, retrieved 2026-11-18)
- Completion: 2030-07-18 (anticipated) (ClinicalTrials.gov record NCT06291376, source copy `cardio:ctgov-nct06291376-2026-10-02`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong SAR China; Israel; Italy; Japan; Malaysia; Netherlands; Poland; Saudi Arabia; Slovakia; South Korea; Spain; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT06291376, source copy `cardio:ctgov-nct06291376-2026-10-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06291376-2026-10-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
- Acronym: I CAN
- Condition: Immunoglobulin A Nephropathy
- Condition: IgAN
- Intervention (Drug): Ravulizumab
- Intervention (Drug): Placebo
- Lead sponsor: Alexion Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Alexion Pharmaceuticals, Inc. (`cardio:org-alexion-pharmaceuticals-inc`)

## Provenance

Content hash: e3ec158a0d356f936d604bbedf77ccc255e6f1de47199e2499e0cbb0f0718cd8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
